u/kavya_kravchenko

Not convinced. You are attributing a week of sulphur burps to the glucagon arm when the escalation rate alone would explain it.

That is the first-month offer price, not the ongoing monthly cost. The tracker records the second one.

private script pricing varies by pharmacy here too

Small fix — amylin analogue, not a GLP-1 analogue. The whole mechanism argument changes on that word.

Employer-sponsored plans have their own criteria and appeal processes, independent of the provincial formulary. Which one applies determines everything about the route.

pharmacy stock and national supply are different questions

I would not treat one pharmacy’s quote as the national price. Variation between them is substantial.

503A is patient-specific, 503B is outsourcing facility, they are not the same thing

Correcting myself: the referral was 17 months ago, not the figure I gave. I keep rounding it down.

read the discussion section, that is where the honesty lives

That is the first-month offer price, not the ongoing monthly cost. The tracker records the second one.

a 503B has to register and report, so there is a paper trail to ask for

Has anything else changed in the same window?

Yes. Approval and coverage are separate, and this board conflates them in about half its threads.

This. A bad fortnight after a step is expected. A bad quarter is a reason to talk to somebody who knows your history.

The thing that surprised me was how much of the discussion here is inference rather than measurement.

Disagree — a 503B being registered does not make its preparations equivalent to an approved product. Different regulatory category entirely.

Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.

Disagree. "More receptors means more effect" is not how any of this works and the trial data does not support the linear story.

Yes — asking which facility, by name, is the single most useful question and most clinics will answer it.

Careful — you have a plausible mechanism and no evidence that it is the operative one in the case you are describing.

Nobody warned me about constipation and I would have liked the warning. It was not dangerous, it was just deeply unpleasant and completely unexpected.

Which day of the week relative to the shot does it hit?

Mine settled at week 59 and has not come back since, across two more steps.

The muscle cramps profile felt different rather than worse. Hard to describe and impossible to quantify, so take it as an impression.

the glucagon component is why the metabolic story reads differently

injection-site soreness for the first eight days after each step, then nothing, every single time. Predictable enough that I started planning my week around it.

A private prescription is an independent route: it does not affect NHS list position, and it is not a step in the same pathway.

Subsidy criteria and authority requirements are published. For eligibility questions those documents are authoritative and this board is not.

Disagree — a 503B being registered does not make its preparations equivalent to an approved product.

yannick_petrov is right about the concentration trap. It breaks arithmetic that has been reliable for months.

Dosing intuitions from the GLP-1 boards do not transfer. Different receptor family, different exposure-response, and no published schedule for members to reason from.

This. Albumin binding and modification are why the half-life is what it is, and it is a design decision rather than an accident.

phase 3 data will change most of what gets said here

Rang three pharmacies for a private price and got three different numbers, all in the same city.

A beyond-use date derived from published stability data means something different from one assigned by default rule. Asking which is a fair question and the answer is usually available.

The effect on gastric emptying is most pronounced early and attenuates with continued dosing, which is the mechanism behind the "it settles at a stable dose" pattern the whole board reports.

England, Scotland, Wales and Northern Ireland are four different pathways

dose response is not linear and nobody should assume it is

The intake asked me three questions and none of them were about my history. That told me everything I needed to know about the model.

the shortage list is the whole legal hinge and people skip it